Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Target-site pharmacokinetics of linezolid in diabetic foot infection
2008-006153-41Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of linezolid in diabetic foot infection (DFI), osteomyelitis (OM) and type 2 diabetes mellitus (T2DM), sponsored by Medical University of Graz. Primary endpoint: Pharmacokinetics of linezolid in inflamed subcutaneous adipose tissue. Started Feb 2009; status: completed.
02
Drugs
linezolid
03
Conditions
diabetic foot infection (DFI)osteomyelitis (OM)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-006153-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006153-41.